Melissa Hughes

Aug 30, 2024 | academic.oup.com | Herbert Wertheim College |Alyssa Pereslete |Melissa Hughes |Nancy Lin

There are limited data regarding HER2-low expression dynamics between matched primary tumors and brain metastases (BrMs) in breast cancer. HER2-low expression has emerged as a new therapeutic biomarker for highly active antibody-drug conjugates with emerging intracranial activity. Patients with metastatic breast cancer (MBC) and BrMs seen at an NCI-designated center between 2003-2023 were identified.